In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

Yanan Xu, Xiaoyin Zhu, Hongbo Wang, Shanyue Sun, Xin Yue & Jingwei Tian

PCC0104005 is a novel drug candidate for treating schizophrenia that displays high affinity for serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D₂, D₃, D₄, serotonin 5-HT₁A, and 5-HT₂A receptors and antagonism at 5-HT₂B, 5-HT₆, and 5-HT₇ receptors. PCC0104005 blocks MK-801-induced hyperactivity in rats, consistent with the reduction in dopamine D₂ receptor stimulation and increased dopamine release in the medial prefrontal cortex. PCC0104005 inhibits 5-HTP-induced head twitches in rats, due to its moderate affinity for human 5-HT₂A receptors (Ki = 5.1 nM). PCC0104005 significantly reduced the escape latency of rats and improved the MK-801-induced memory impairment. In the object recognition experiment, PCC0104005 significantly improved the recognition disorder induced by MK-801. PCC0104005 did not significantly increase the plasma prolactin level, which is thought to be related to the preferential affinity of PCC0104005 for dopamine D₂ receptors compared with 5-HT₁A receptors, as well as the relative antagonistic activity toward the D₂ receptor. Due to its 5-HT₂A agonism, PCC0104005 does not produce catalepsy in mice, a behaviour predictive of the occurrence of extra-pyramidal syndrome (EPS) in humans. PCC0104005 has unique affinities for dopamine receptors and serotonin receptors, which may lead to clinical advantages, as well as fewer adverse reactions.

Schizophrenia is a major neuropsychiatric disorder that affects more than 1% of the global population. It is characterized by hallucinations and delusions of experience, known as “positive” symptoms, as well as various other symptoms, including reduced social function and speech, emotional deprivation, the confusion of thought, and low motivation, known as “negative” symptoms. Cognitive dysfunction is also a central feature of schizophrenia. The treatment of schizophrenia, now known as “typical” antipsychotic drugs that exert a common strong inhibitory effect on the D₂ class of dopamine receptors, has undergone a revolutionary change since the first generation of antipsychotic drugs were developed 60 years ago.

The use of a typical antipsychotic medication is an effective way to reduce the positive symptoms in many patients. Because of its potent D₂ receptor antagonism in the substantia nigra striatum in the motor system, its utility is limited by severe side effects, including acute Parkinson’s disease disorders and dystonia, commonly known as extrapyramidal symptoms (EPS), and drug-induced delayed dyskinesia.

One of the key issues in the excitatory action of D₂ is to determine its optimal level of intrinsic activity. When the intrinsic activity of the drug at the D₂ receptor is too high, a lack of potent clinical activity and a greater number of side effects are observed that increase the tension of D₂ receptors, including nausea, vomiting, insomnia, and motor effects, whereas excessive D₂ antagonist activity results in an increased risk of EPS by increasing prolactin secretion. It has been reported that antipsychotic responses and extrapyramidal side effects (EPS) may be related to D₂ receptor occupancy, albeit with different thresholds. With typical antipsychotics, a D₂ receptor occupancy in the range of 70% was associated with the clinical response, whereas EPS emerged at a D₂ receptor occupancy of 80%. The main strategy for treating schizophrenia is based on antagonizing dopamine D₂ receptors. However,
due to the problem of tolerance, treatment with D2 receptor antagonists is not considered the optimal strategy for regulating dopaminergic activity, and the discovery and development of D2 receptor partial agonists provides stable dopamine function in an affordable treatment. In addition, most second-generation antipsychotics are serotonin 5-HT2A receptor and adrenergic α1 receptor antagonists, and individual compounds have an effect on a variety of other monoamine receptors, such as the 5-HT1A receptor. These broad target effects also improve the efficacy of antipsychotic drugs (with additional effects on emotional symptoms or cognitive disorders) or mitigate adverse effects [e.g., EPS]9,10. Multiple evidences suggest that schizophrenia may be associated with glutamate dysfunction[11,12]. NMDA receptor antagonists can aggravate symptoms in patients with schizophrenia[13,14]. In rats, the highly selective non-competitive NMDA receptor antagonist, MK-801, induces hyperlocomotion and other signs of disorganized behaviour[15]. These findings have led to the use of MK-801-treated rodents as models for schizophrenia1. Although the drug-based acute effects do not contain developmental components when applied to adult animals, however, this model shows good predictive validity, and importantly, it triggers many symptoms similar to those in Symptoms observed in affected human subjects[16]. A new antipsychotic medication acting synergistically via serotoninergic, dopaminergic, and glutamatergic receptors that is able to improve the social functioning of patients while addressing positive symptoms of the disease with a lower incidence of EPS would be of tremendous benefit to patients with schizophrenia. Here, we describe the biochemical and behavioural characterization of PCC0104005, a novel small-molecule therapeutic agent displaying the combined properties of dopamine D2 receptor antagonism and serotonin transporter binding, which is currently in development for the treatment of schizophrenia. The findings provide a new drug option for antipsychotic treatment.

Results
Receptor binding profile analysis. The structure of PCC0104005, a hydrochloric acid, is shown in Fig. 1. Binding affinities of the compound for receptors implicated in the therapeutic actions of antipsychotic medications, including serotonin receptors, dopamine receptors, adrenergic receptors and histamine H1 receptors are shown in Table 1. PCC0104005 displays high-affinity binding to the D2 receptors, with a Ki = 0.11 nM, and the D3 receptors, with a Ki = 0.14 nM. Aripiprazole has higher affinities for 5-HT1A receptors than PCC0104005 (Ki = 3.4 nM and 5.1 nM, respectively). PCC0104005 possesses a higher selectivity for D2 receptors than 5-HT2A receptors. When the antipsychotic medications are adrenergic 5-HT1C receptor and histamine H1 receptor antagonists, it is more likely to cause adverse reactions. However, PCC0104005 also displayed high affinity for H1 receptors, with a Ki = 1.1 nM, that may cause EPS and other adverse reactions. Compared to risperidone, PCC0104005 displayed moderate affinity for 5-HT1C receptors (Ki = 12 nM and Ki = 36 nM, respectively), which is conducive to reducing abnormal glucose and lipid metabolism, weight gain and other adverse reactions.

Reversal of MK-801-induced locomotor hyperactivity in rats. The MK-801 treatment gradually increased activity and reached a stable level after approximately 10 minutes (distance travelled = 4933 ± 275.6 mm), thus maintaining stability for at least 60 minutes after injection. Aripiprazole and risperidone significantly reduced MK-801-induced hyperactivity in rats (distance travelled = 1957 ± 455.1 mm, F(1,14) = 47.124, P = 0.000 and distance travelled = 1886 ± 437.3 mm, F(1,14) = 52.954, P = 0.000, respectively). All three doses of PCC0104005 significantly inhibited the locomotor hyperactivity induced by MK-801 in rats (distance travelled = 3284 ± 220.7 mm, P = 0.004, 2646 ± 235.2 mm, P = 0.000, and 2655 ± 286.5 mm, P = 0.000, respectively, F(3,28) = 23.829, P < 0.001). The distance travelled by rats in the 3.0 mg/kg and 6.0 mg/kg PCC0104005 groups was similar to the aripiprazole and risperidone groups (F(3,28) = 3.110, P > 0.05) (Fig. 2). When administered alone, PCC0104005 had no significant effect on spontaneous activity in rats (distance travelled = 1885 ± 269.7 mm). Other stereotypic behaviours, such as licking or grooming, were the same as saline-treated animals upon a visual examination (during the 20-min period following MK-801 administration).
Head twitch behaviour induced by 5-HTP in rats. According to the one-way ANOVA, 5-HTP can significantly induce rat head twitches compared with the control group (52.5 ± 2.57, 2.71 ± 0.88, respectively, F(1,14) = 335.196, P = 0.000). As expected, aripiprazole and risperidone potently blocked 5-HTP-induced head twitches (31.5 ± 3.12, F(1,14) = 37.305, P = 0.01 and 9 ± 1.73, F(1,14) = 196.963, P = 0.000, respectively). PCC0104005 significantly inhibited head twitches induced by 5-HTP (20.17 ± 2.70, 24.86 ± 4.35, and 10.71 ± 4.81, respectively, F(3,28) = 29.990, P = 0.000) (Fig. 3). The effect of PCC0104005 was superior to aripiprazole, but only the group treated with 6.0 mg/kg PCC0104005 showed a significant difference compared with aripiprazole (F(1,14) = 19.083, P = 0.001) and have no significant difference compared to the control group. These data are consistent with the functional activity of PCC0104005 as a 5-HT2A receptor antagonist in vivo.

Effects of the acute administration of PCC0104005 on the learning and memory of MK-801-treated rats in the Morris water maze test. The Morris water maze is a preferred classic experiment that is widely used to study spatial learning and memory as correlates of brain function. Escape latency refers to the time the animal requires to locate the platform and is used to evaluate the animal’s learning and memory abilities. MK-801 significantly impaired learning and memory, as measured by the escape latency, compared to the control animals (35.67 ± 4.05 s and 12.38 ± 2.16 s, F(1,14) = 43.692, P = 0.000). As expected, aripiprazole and risperidone significantly decreased the escape latency (21.71 ± 0.86 s and 20.71 ± 2.18 s), suggesting that they exerted...
some beneficial effects on cognitive performance. The escape latencies of the 1.5, 3.0, 6.0 mg/kg PCC0104005 groups were significantly shorter than the model rats (20.60 ± 1.30 s, F(1,14) = 20.805, P = 0.002, 18.35 ± 2.76 s, F(1,14) = 22.318, P = 0.000, 17.45 ± 1.78 s, F(1,14) = 29.447, P = 0.000, respectively) (Fig. 4). PCC0104005 significantly decreased the escape latency, indicating that it improved spatial memory in SD rats treated with MK-801.

A significant difference in the latency period was not observed among the PCC0104005 groups and aripiprazole group (F(3.28) = 2.117, P = 0.113).

Effects of subchronic (sc) administration of PCC0104005 on the learning and memory of MK-801-treated rats in the Morris water maze test. According to the one-way ANOVA, MK-801 significantly impaired learning and memory, as measured by the escape latency, compared to the control animals (25.56 ± 4.36 s and 9.75 ± 2.52 s, F(1,14) = 40.883, P = 0.002). As expected, risperidone significantly decreased the escape latency (11.81 ± 3.06 s, F(1,14) = 26.071, P = 0.006), suggesting that it exerted some beneficial effects on cognitive performance. However, the escape latency of aripiprazole-treated animals was significantly extended (31.83 ± 5.00 s) for as yet unknown reasons. The escape latencies of the 1.5, 3.0, 6.0 mg/kg PCC0104005 groups were significantly shorter than the model rats (9.85 ± 1.80 s, F(1,14) = 46.420, P = 0.000; 11.45 ± 2.70 s, F(1,14) = 30.781, P = 0.000; 14.88 ± 2.95 s, F(1,14) = 3.05, P = 0.036, respectively) (Fig. 5). PCC0104005 significantly decreased the escape latency, indicating that it improved spatial memory in SD rats treated with MK-801. A significant difference in the latency period was not observed among the PCC0104005 groups and aripiprazole group (F(3.28) = 2.117, P = 0.113).

Novel object recognition test. As early as 1950, Berlyne observed that rats spent significantly more time exploring a novel object than two familiar objects. Subsequently, the novel object recognition (NOR) task was developed, based on the natural propensity of rats to explore novel objects. It is a non-rewarding, ethologically relevant, relatively simple test. Such tests are increasingly being used to study and screen potential novel antipsychotic drugs. Indeed, the NOR task has been listed under the TURNS initiative as relevant for studying visual learning and memory deficits in schizophrenia (TURNS.ucla.edu).

Two-way ANOVA did not show a significant effect of the treatment group or a difference in the time spent exploring two identical objects during the Acquisition Trial of the NOR task. A paired t test confirmed the lack of discrimination between the identical objects in all groups (Fig. 6A). During the 10-min Retention Trial, two-way ANOVA revealed a significant discrimination between the familiar and novel object (P < 0.01) and a significant
The paired sample t test did not reveal a significant difference in the time the MK-801-treated rats spent exploring the novel and the familiar objects in the Retention Trial. Compared with the model group, drug-treated groups displayed a significant increase in the time spent exploring the novel object compared with the familiar object (Fig. 6). One-way ANOVA revealed a significant difference in DI between the model group and control group (0.51 ± 0.04 and 0.84 ± 0.03, P = 0.01). PCC0104005, aripiprazole and risperidone improved the effects.

Measurement of forelimb catalepsy in mice. We tested the compound for the induction of forelimb catalepsy in mice to further examine the potential for PCC0104005 to induce motor side effects. Mice receiving oral aripiprazole and risperidone treatments showed obvious forelimb catalepsy compared to the control mice (28.84 ± 4.72 s, F(1,14) = 0.657, P = 0.008 and 63.69 ± 4.57 s, F(1,14) = 99.27, P = 0.000). Mice in the 4.0 mg/kg PCC0104005 group displayed a statistically significant increase in forelimb catalepsy compared with the control group (25.89 ± 3.59 s and 12.77 ± 0.75 s, F(1,14) = 7.357, P = 0.017) as measured in the grip test (Fig. 7). In contrast, mice in the 2.0 mg/kg and 8.0 mg/kg PCC0104005 groups did not exhibit significant forelimb catalepsy (22.56 ± 2.65 s and 21.23 ± 2.53 s), suggesting that PCC0104005 does not increase the risk of catalepsy. In addition, mice treated with PCC0104005 left the steel rod within a significantly shorter time than aripiprazole-treated mice (P < 0.01).

Effects on plasma prolactin, total cholesterol or triglyceride levels in rats. Plasma prolactin levels were assessed as described in detail by Cosi et al. (2006). Aripiprazole produced an increase in prolactin plasma levels, but the difference was not significant compared with the control group (4.09 ± 1.31 ng/ml and 0.869 ± 0.139 ng/ml, F(1,4) = 4.664, P = 0.139). Risperidone produced a significant increase in prolactin plasma levels (5.67 ± 0.51 ng/ml, F(1,4) = 56.877, P = 0.002), whereas only 6.0 mg/kg PCC0104005 significantly increased the plasma prolactin levels (4.32 ± 0.66 ng/ml, F(1,4) = 18.380, P = 0.013) (Fig. 8A). The 1.5 mg/kg and 3.0 mg/kg PCC0104005 treatments also increased the prolactin levels, but the difference was not significant compared with the control group (2.48 ± 0.77 ng/ml, F(1,4) = 5.601, P = 0.077 and 3.45 ± 2.17 ng/ml, F(1,4) = 3.038, P = 0.310). Compared with the control group, the body weights of rats in each experimental group were significantly increased (110.0 ± 6.54 g, 107.5 ± 4.43 g, 121.7 ± 9.54 g for 1.5, 3.0, and 6.0 mg/kg PCC0104005, respectively;
110.8 ± 7.12 g for aripiprazole and 116.4 ± 10.51 g for risperidone), but the differences among each treated group were not significant (p > 0.05). The plasma total cholesterol (TC) and triglyceride levels were not significantly different compared to the control group (P > 0.05) (Fig. 8B,C).

**Discussion**

It is known that alterations in the function of the prefrontal cortex may contribute or even play a substantial role in disrupted flexibility observed in schizophrenia and its animal models. It has been shown that MK-801 produces hyperlocomotion and perhaps most importantly a deficit in various cognitive domains. Thus, the most probable explanation for the significant antagonism of the MK-801-induced locomotor hyperactivity is
Figure 7. The effect of PCC0104005 on catalepsy duration in mice. Mice were administered an oral dose of vehicle alone (0.5% methylcellulose in water, 1 ml/kg) or PCC0104005 (2.0, 4.0, or 8.0 mg/kg), aripiprazole (2.0 mg/kg) or risperidone (Ris, 0.25 mg/kg) 1 h before the test. The longest duration of catalepsy in each mouse was recorded. Results are presented as mean ± S.E.M. (n = 8). *P < 0.05, **P < 0.01 drug delivery groups vs. the control group.

Figure 8. The adverse reactions that may be caused by PCC0104005. Rats were administered vehicle alone, PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (Ari, 1.5 mg/kg, i.g.) or risperidone (Ris, 0.2 mg/kg) for 28 days before testing. Results are presented as mean ± S.E.M. (n = 3–5). (A) Plasma prolactin levels in different groups. Plasma prolactin levels were assessed using a commercially available Prolactin ELISA Kit. *P < 0.05, **P < 0.01 drug delivery groups vs. the control group. (B, C) Plasma total cholesterol and triglyceride levels in different groups. (D) Weight changes in different groups. *P < 0.05, **P < 0.01 drug delivery groups vs. the control group.
that PCC0104005 or aripiprazole block MK-801-evoked dopamine release. PCC0104005 is a D₂ receptor partial agonist (Ki = 0.11 nM), consistent with current clinical studies. The hyperactivity induced by MK-801 was decreased in PCC0104005-treated rats, consistent with the reduction in dopamine D₂ receptor stimulation. The high affinity of PCC0104005 for the D₂ receptor is speculated to exert beneficial effects on positive symptoms, but may be accompanied by an increased incidence of adverse effects, such as EPS and hyperprolactinemia. Simultaneously, the potential for D₂ antagonist-like adverse effects (e.g., EPS and hyperprolactinemia) may be lower than other D₂ receptor antagonist antipsychotics. Although PCC0104005 has high affinity for the D₂ receptor, it also shows fewer adverse reactions in animals, which may result in clinical advantages.

Antipsychotic drugs targeting dopamine D₂ receptors may affect the positive symptoms of schizophrenia; however, drugs targeting non-DA D₂ receptors (DA D₁, D₃, and D₄), serotonin receptors (5-HT₂A, 5-HT₁A, 5-HT₃, 5-HT₆), alpha-adrenergic receptors and other neurotransmitters are considered effective treatments for the negative symptoms of schizophrenia. PCC0104005 has a moderate affinity for human 5-HT₂A receptors (Ki = 5.1 nM) and significantly inhibited the 5-HTP induced head twitch behaviour. 5-HTP is a precursor of 5-HT and is converted to 5-HT by degradation in vivo. The negative symptoms of schizophrenia may be associated with 5-HT₂A and 5-HT₃A. Antagonism of 5-HT₂A receptors is the primary mechanism involved in head twitching. 5-HT₁A partial agonism slightly increased the release of substantia nigral and striatal DA to reduce the extrapyramidal response. 5-HT₂A partial agonism blocks the 5-HT₂A receptor in the prefrontal cortex, while increasing DA release and improving the negative symptoms. At the same time, 5-HT₁A receptor partial agonistic effect is believed to contribute to antipsychotic activity, while reducing a variety of adverse reactions.

The high affinity 5-HT₂A/dopamine D₂ receptor is associated with successful treatment of the negative symptoms of schizophrenia, and these effects may be important for the relief of cognitive dysfunction. In previous studies, serotonin and adrenergic receptor-selective ligands (such as WAY-100635, M100907 and others) improved cognitive impairments in various NMDA receptor antagonist-induced animal models. In our study, PCC0104005 and aripiprazole reversed MK-801-induced deficits, potentially by interacting with serotonin receptors and adrenoceptors.

NMDAR antagonists cause rodent dysfunction and are the most widely used model for studying memory deficits associated with schizophrenia. MK-801 has been shown to induce a deficit in acquisition in the Morris water maze, object recognition task and other tests of relational and spatial memory including the active place avoidance task. It is currently believed that the efficacy of atypical antipsychotics drugs, compared with antipsychotics drugs, in reversing the NOR deficit of NMDAR antagonists is thought to be explained by their greater affinity for 5-HT₂A over the dopamine D₁ receptor. It is generally considered that 5-HT agonism or antagonism contributes to the ability of antipsychotics at sub-D₂ blocking doses to ameliorate cognitive impairments and negative symptoms in schizophrenia. We have shown that NMDAR antagonist reduces parvalbumin expression in GABAergic interneurons in the frontal cortex, dentate gyrus and the CA2/3 region of the hippocampus.

In our study, MK-801 increased the escape latency during the test period indicating that MK-801 impaired the reference spatial memory. Risperidone exhibited stronger blockade of dopamine D₂ receptors compared to aripiprazole and PCC0104005, which may contribute to cognitive impairment observed in SD rats. Based on the results of our study, PCC0104005 significantly reduced the escape latency of rats and improved MK-801-induced memory impairments, but the differences were not significant compared to aripiprazole, consistent with the current clinical findings.

As expected, MK-801-induced recognition memory impairments were attenuated by PCC0104005. These data are completely consistent with the effects of other atypical and novel antipsychotics, such as clozapine, risperidone, and aripiprazole, on performance in this reversal learning task. PCC0104005, the selective 5-HT₂A receptor partial agonism and the 5-HT₁A receptor antagonist, attenuated the deficits in the NOR task induced by an NMDA receptor antagonist. PCC0104005 had a lower 5-HT₁A receptor occupancy at given D₂ receptor occupancy, which may lead to clinical advantages. High affinity for and selectivity toward the dopamine D₃ receptor distinguishes PCC0104005 from compounds like risperidone, which was reported to possess antipsychotic-like properties. Partial agonism at D₃ receptors is involved in the antipsychotic and proconvulsive profiles, as well as effects on affective states.

PCC0104005 did not significantly increase the plasma prolactin level, which may be related to the preferential affinity of PCC0104005 for dopamine D₂ receptors than 5-HT₂A receptors, and the relative antagonistic activity toward the D₃ receptor. This finding emphasizes the importance of the precise balance of DA D₂ antagonism versus 5-HT₂A agonism for the optimal pharmacological activity of a new generation antipsychotics targeting both of these receptors, which requires further discussion. PCC0104005 has fewer adverse reactions in animals, which may result in clinical advantages.

The consequences of the affinities of PCC0104005 for (and antagonist effects on) α₂ and α₂B-adrenoceptors are more difficult to predict because of the lack of selective compounds for studying the functional importance of these receptors. Based on results obtained from genetically modified mice, α₂B antagonism may contribute to antipsychotic-like activity and effects on stimulant-induced reward. Inhibition of peripheral α₂B-adrenoceptors (for which brexpiprazole and aripiprazole have moderate affinities) is thought to be important for the regulation of blood pressure, but may not contribute to the overall effects. PCC0104005 has high affinity for H₁ and 5-HT₂C receptors and may have a tendency to cause side effects such as sedation and weight gain.

The main findings are summarized below. (1) PCC0104005 induced behavioural effects consistent with dopamine D₂ receptor blockade and antagonism at the 5-HT₂A receptor. (2) A well-balanced combination of dopamine receptors and serotonin receptors confers a favourable behavioural profile on PCC0104005, characterized by efficacy in models predictive of antipsychotic activity (dopamine D₂ receptor partial agonism), together with a lack of cataleptogenic activity or serotonin syndrome induction (3) PCC0104005 alone had no detrimental effect on these locomotor hyperactivity model.
Therapeutic potential of PCC0104005. PCC0104005 is non-inferior compared with similar anti-schizophrenic drugs such as aripiprazole and provides new drug candidates for the treatment of schizophrenia. Ultimately, the potential of PCC0104005 for the treatment of schizophrenia and other psychiatric and neurological disorders awaits further study in humans. The compound is currently under investigation in advanced human clinical studies.

Materials and Methods

Drugs. PCC0104005, a hydrochloric acid, was synthesized at ShanDong Luye Pharmaceutical Ltd. Aripiprazole was obtained from Otsuka Pharmaceutical Europe, Bristol-Myers Squibb Polska. Risperidone was obtained from Xian Janssen Pharmaceutical Ltd. MK-801 and 5-HTP was obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). All receptor binding studies were performed by Cerep Panlabs.

PCC0104005, aripiprazole and risperidone were dissolved in solution of 0.5% (w/v) methylcellulose (400 cP, #M0430, Sigma-Aldrich Chemical Co., Inc.) in saline. Oral dosing solutions were prepared fresh daily. MK-801 and 5-HTP were dissolved in physiological saline and protected from light.

Animals. Male NIH mice (20–25 g) and Sprague-Dawley (SD) rats (180–220 g) obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. were used for behavioural experiments and measurements of adverse reactions. In all cases, animals were maintained under standard laboratory conditions on a 12-h light/dark cycle with food and water available ad libitum and a minimum of a 1-week acclimation period prior to experimentation. This acclimation period was established to reduce the potential stress and agitation associated with transportation and handling. All experiments were conducted in accordance with the guidelines of the Ministry of Health of PR China and the Animal Care Committee of China Medical University. The study protocol was approved by the Experimental Animal Research Committee of Yantai University.

In vitro binding affinity. The affinity of compounds for the human dopamine D_2, D_3, D_4, 5-HT_2A, 5-HT_2B, 5-HT_2C, 5-HT_3, 5-HT_4, H_1, α_1A, and α_1B receptors in transfected HEK-293 cells was determined using a radioligand binding assay. Cell membrane homogenates were incubated in the absence or presence of the test compound in a buffer. Nonspecific binding was measured in the presence of the standard reference compound. Following incubation, samples were rapidly filtered under a vacuum through glass fibre filters (GF/B, Packard) presoaked with 0.3% PEI and rinsed several times with ice-cold 50 mM Tris-HCl using a 96-sample cell harvester (Unifilter, Packard). Filters were dried and then radioactivity was counted in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint 0, Packard). The results are expressed as percent inhibition of the specific binding of the radioligand in the control. The standard reference compound was tested in each experiment at several concentrations to obtain a competition curve from which its Ki was calculated.

Inhibition of MK-801-induced hyperactivity. SD rats (200–250 g, 8 animals/group) were habituated to activity chambers (grey PVC boxes 60*60 cm wide and 45 cm deep) comprising the TopScan monitoring system (CleverSys Inc.) and were maintained in a quiet observation room under low light conditions for at least 1 h before recording their activities. Rats were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) 1 h before test. Then, all animals were intraperitoneally injected with 0.9% saline or MK-801 (0.3 mg/kg) 10 minutes before test. Animals were returned to the activity chambers after the intraperitoneal injection, and locomotor activity as quantitated as the distance travelled (mm) was recorded for 10 to 20 minutes using the TopScan monitoring system. The end of each trial, the faecal boli were cleaned to avoid the potential influence of intramaze cues (odour trails, etc.) on the rats.

Determination of 5-HTP-induced head twitch. SD rats (200–250 g, 8 animals/group) were housed in the test room for at least 1 h before the experiment. Rats were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) 1 h before the test. Then, all animals were intraperitoneally injected with 0.9% saline or 5-HTP (320 mg/kg) 40 min before the test. The number of head twitches was recorded during a period of 40–70 min after intraperitoneal injection.

Effects of the acute administration on the learning and memory of MK-801-treated rats in the Morris water maze (MWM) test. SD rats (200–250 g, 8 animals/group) were trained continuously until all rats found the platform within 30 sec, and the training time depended on the training results. On the test day, rats were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) 1 h before the test. Then, all animals were intraperitoneal injections of 0.9% saline or MK-801 (0.2 mg/kg, i.p.) 30 minutes before the test. The test was started and the escape latency of rats was measured during the test in which platform was not withdrawn. A trial was deemed complete as soon as the rat had located platform or when 60 s had elapsed, whichever occurred first. The swimming activity of each rat was monitored by TopScan monitoring system. At the end of each trial, the faecal boli were cleaned to avoid the potential influence of intramaze cues (odour trails, etc.) on the rats.

Effects of the subchronic administration on the learning and memory of MK-801-treated rats in the MWM test. SD rats (200–250 g, 8 animals/group) were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) for 28 days. Beginning on the 15th day, rats were intraperitoneally injected with 0.9% saline or MK-801 (0.3 mg/kg) to the 28th day. The MWM test was started after the last injection. Each rat was trained in 4 trials per day for 5 consecutive days. The escape latency to find the submerged escape platform in the water maze.
was recorded with the TopScan monitoring system. Each training session lasted for a maximum of 60 s. If the escape latency exceeded 60 s, it was recorded as 60 s and the rat was manually guided to the platform. On day 6, the platform was removed and each rat was allowed to swim freely for 60 s.

**Novel object recognition (NOR) test.** SD rats (200–250 g, 8 animals/group) were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) for 28 days. Beginning on the 15th day, rats were intraperitoneally injected with 0.9% saline or MK-801 (0.3 mg/kg) to the 28th day. Rats were tested after the last administration. Following a 10-min habituation session on the day of testing, each rat was placed in the NOR chamber (grey PVC boxes 60×60 cm wide and 45 cm deep) and exposed to two identical objects (Left and Right) for a period of 10 min (Acquisition Trial). The objects used in this experiment were rectangular plastic cases. The heights of the objects were comparable (10 ± 2 cm), and they were heavy enough to ensure that they would not be displaced by the animals. Rats were then returned to their home cage for an inter-trial interval (ITI) of 1.5 h and the entire box was cleaned. Then one was replaced with an identical familiar copy and one was replaced with a novel object. Following the ITI, rats were returned to the apparatus and allowed to explore the familiar and novel objects in the test box for a 10-min retention trial (Retention Trial). All experiments were monitored by TopScan monitoring system.

**Measurement of forelimb catalepsy in mice.** Mice were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (2.0, 4.0, or 8.0 mg/kg), aripiprazole (2.0 mg/kg) or risperidone (0.25 mg/kg) 1 h before the test. Then each mouse was positioned such that both front paws rested on a 0.4 mm diameter steel rod (covered with non-slippery tape) placed 3.5 cm above the surface of the bench. The period of time that each mouse maintained this position was recorded. The experiment was repeated at least 10 times. Finally, the longest period of catalepsy for each mouse was recorded.

**Effects on plasma prolactin, total cholesterol (TC) or triglyceride levels in rats.** Rats were administered an oral dose of vehicle alone (0.5% methylcellulose, 1 ml/kg), PCC0104005 (1.5, 3.0, or 6.0 mg/kg), aripiprazole (1.5 mg/kg) or risperidone (0.2 mg/kg) for 1 month. Plasma prolactin levels were assessed using a commercially available Prolactin ELISA (Mouse/Rat) purchased from GenWay, according to the manufacturer's instructions. Plasma TC and triglyceride levels were assessed using a Roche automatic biochemical analyser Cobas c 311.

**Statistical analysis.** All data are expressed as the mean ± S.E.M. Between-group differences were analysed with SPSS software using one-way analysis of variance (ANOVA) and the least significance difference (LSD) post hoc test. Data from the same animals evaluated on several occasions were analysed using between-within univariate or multivariate ANOVA for repeated measures. Exploration data (in the acquisition and retention trials) in Novel object recognition test were analyzed by a two-way analysis of variance (ANOVA) followed by the pair-wise comparison when a significant effect was detected by the ANOVA. DI data was analyzed by one-way ANOVA followed by post hoc Bonferroni test when a significant effect was detected by ANOVA.

**References**

1. Snyder, G. L. et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. *Psychopharmacology* 232, 605–621, https://doi.org/10.1007/s00213-014-3704-1 (2015).
2. HERBERT Y. MELTZER, SHIGEHIRO, Accepted for publication June 29, MATSUBARA & LEE, a. J.-C. Classification of Typical and Atypical Antipsychotic Drugs on the Basis of Dopamine, D-2 and Serotonin2 pK Values.1. *The Journal of Pharmacology and Experimental Copyright* 0022-3566/99/251-0238(1988).
3. Richard, S. E. et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. *Arch Gen Psychiatry.* 64, 633–647 (2007).
4. LANCRE, D. R., REID, S. S. & ROYER, H. Snyder. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antipsychotic Medications. *Science* 192, 481–483 (1976).
5. Davis, K. L. et al. Dopamine in schizophrenia: a review and reconceptualization. *The American Journal of Psychiatry* 148(11), 1474 (1991).
6. Maeda, K. et al. Brexpiprazole II: antipsychotic-like and preocognitive effects of a novel serotonin-dopamine activity modulator. *The Journal of pharmacology and experimental therapeutics* 350, 605–614, https://doi.org/10.1124/jpet.114.213819 (2014).
7. Casey, D. E., Sands, E. E., Heisterberg, J. & Yang, H. M. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. *Psychopharmacology* 200, 317–331, https://doi.org/10.1007/s00213-008-1207-7 (2008).
8. Maeda, K. et al. Brexpiprazole I: in vivo characterization of a novel serotonin-dopamine activity modulator. *The Journal of pharmacology and experimental therapeutics* 350, 589–604, https://doi.org/10.1124/jpet.114.213793 (2014).
9. Meltzer, H. Y. The Role of Serotonin in Antipsychotic Drug Action. *Neuropsychopharmacology* 21, 106S–115S, https://doi.org/10.1016/S0893-133X(99)00046-9 (1999).
10. Paulson, L., Martin, P., Ljung, E., Blennow, K. & Davidson, P. Effects on rat thalamic proteme by acute and subchronic MK-801-treatment. *European journal of pharmacology* 505, 103–109, https://doi.org/10.1016/j.ejphar.2004.10.036 (2004).
11. Goff, D. C. & Coyle, J. T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. *Arch Gen Psychiatry* 55, 985–996 (1998).
12. George, R. & Breese*, D. J. K. & Sheryl, S. Moy. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. *Neuroscience and biobehavioral reviews* 26, 441–455 (2002).
13. Labiri, A. C., Lajarte, D. & Tammingsa CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 13(1), 9–19(1995).
14. Bubenikova, V. et al. The effect of tryptophan depletion on the action of haloperidol in MK-801-treated rats. *European journal of pharmacology* 502, 109–116, https://doi.org/10.1016/j.ejphar.2004.08.034 (2004).
16. Lobellova, V. et al. Two learning tasks provide evidence for disrupted behavioural flexibility in an animal model of schizophrenia-like behaviour induced by acute MK-801: a dose-response study. *Behavioural brain research* **246**, 55–62, https://doi.org/10.1016/j.bbr.2013.03.006 (2013).

17. Nilsson, M., S. W. N. & Waters, A. Carlsson. A behavioural pattern analysis of hypoglutamatergic mice – effects of four different antipsychotic agents. *Journal of neural transmission* **108**, 1181–1196 (2001).

18. Rung, J. P., Carlsson, A., Ryder Markinhult, K. & Carlsson, M. L. (+)MK-801 induced social withdrawal in rats: a model for negative symptoms of schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry* **29**, 827–832, https://doi.org/10.1016/j.pnpbp.2005.03.004 (2005).

19. Bath, L. et al. RP5663, a novel, multimodal, serotonin receptor modulator, prevents monosodium-induced pulmonary arterial hypertension in rats. *European journal of pharmacology* **810**, 92–99, https://doi.org/10.1016/j.ejphar.2017.05.048 (2017).

20. Sprague, D. A., Loewen, P. S. & Raymond, C. B. Selection of atypical antipsychotics for the management of schizophrenia. *The Annals of pharmacotherapy* **38**, 313–319, https://doi.org/10.1345/aph.1C461 (2004).

21. Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular psychiatry* **10**, 79–104, https://doi.org/10.1038/sj.mp.4001556 (2005).

22. Louaftis, Z. G. & Luckhaus, C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. *The international journal of neuropsychopharmacology* **17**, 823–832, https://doi.org/10.1017/S1461545713001417 (2014).

23. Snigdha, S. et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. *The Journal of pharmacology and experimental therapeutics* **332**, 622–631, https://doi.org/10.1124/jpet.109.156349 (2010).

24. Mutlu, O., Uğur, C., Celikyurt, I. K., Akar, F. Y. & Erden, F. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. *Pharmacology, biochemistry, and behavior* **98**, 398–404, https://doi.org/10.1016/j.pbb.2011.02.009 (2011).

25. Meneses, A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshrinking Pavlovian/instrumental learning task. *Behavioural brain research* **155**, 275–282, https://doi.org/10.1016/j.bbr.2004.04.026 (2004).

26. Blot, K., Bai, J. & Otani, S. The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animal model for cognitive symptoms of schizophrenia. *Journal of physiology, Paris* **107**, 448–451, https://doi.org/10.1016/j.jphysparis.2013.04.003 (2013).

27. Meltzer, H. Y. et al. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. *The international journal of neuropsychopharmacology* **16**, 2181–2194, https://doi.org/10.1016/j.jinp.2013.09.005 (2013).

28. Abdel-Monim, Z., Neill, J. C. & Reynolds, G. P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. *Journal of pharmacology & toxicology* **21(2)**, 198–205 (2007).

29. Reynolds, G. P. & Neill, J. C. Modelling the cognitive and neuropharmacological features of schizophrenia with phencyclidine. *Journal of pharmacochemistry* **30**, 1141–1144, https://doi.org/10.1016/j.26988116666766 (2016).

30. Grayson, B., Idris, N. F. & Neill, J. C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. *Behavioural brain research* **184**, 31–38, https://doi.org/10.1016/j.bbr.2007.06.012 (2007).

31. Depoortere, R. et al. F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. *British journal of pharmacology* **151**, 266–277, https://doi.org/10.1038/sj.bjp.0707160 (2007).

32. Gross, G. & Drecher, K. The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. *Handbook of experimental pharmacology*, 167–210, https://doi.org/10.1007/978-3-642-25758-2_7 (2012).

33. Drouin, L. Darraçq, S. Coteccia, F. Trovero & Tassin1, a. J.-P. α1B-Adrenergic Receptors Control Locomotor and Rewarding Effects of Psychostimulants and Opiates. (2002).

34. Kiss, B. et al. Cariprazine (RGT-188), a dopamine D3 receptor-prefering, D3(D/2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. *The Journal of pharmacology and experimental therapeutics* **333**, 328–340, https://doi.org/10.1124/jpet.109.160432 (2010).

35. Kroeze, W. K. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* **28**, 519–526, https://doi.org/10.1038/sj.npp.1300027 (2003).

36. Gururajana, A., Taylor, D. A. & Malone, D. T. Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. *Journal of pharmacology & toxicology* **26**, 1337–1332, https://doi.org/10.1007/s00213-012-441865 (2012).

37. Hou, J. et al. In vitro and in vivo characterization of PA01, a novel promising tripeptide uptake inhibitor. *Physiology & behavior* **138**, 141–149, https://doi.org/10.1016/j.physbeh.2014.10.007 (2015).

38. Enomoto, T. et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. *Behavioural brain research* **186**, 197–207, https://doi.org/10.1016/j.bbr.2007.08.012 (2008).

39. Idris, N. et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. *Psychopharmacology* **208**, 23–36, https://doi.org/10.1007/s00213-009-1702-5 (2010).

40. Kulkova, E. A. et al. Alteration of the brain morphology and the response to the acute stress in the recombinant mouse lines with different predisposition to catalepsy. *Neuroscience research* **117**, 14–21, https://doi.org/10.1016/j.neurese.2016.11.009 (2017).

Acknowledgements
This work was partially supported by the National Natural Science Foundation of China (NO. 81473188) and the Key Project of Shandong Province (No. 2017GSF218106).

Author Contributions
Yanan Xu and Xiaoyin Zhu designed the research and wrote the manuscript; Yanan Xu and Xiaoyin Zhu performed the majority of the experiments; Shanyue Sun and Xin Yue supported several experiments. Jingwei Tian and Hongbo Wang contributed materials and revised the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
